Kiora Pharmaceuticals, Inc.
KPRX
$3.28
$0.06411.99%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 0.00 | -- | -- | 16.00M | -- |
Total Other Revenue | 0.00 | -- | 20.00K | -- | -- |
Total Revenue | 0.00 | -- | 20.00K | 16.00M | -- |
Cost of Revenue | -3.34M | 1.32M | 906.70K | 1.49M | -2.51M |
Gross Profit | 3.34M | -1.32M | -886.70K | 14.51M | 2.51M |
SG&A Expenses | 1.33M | 1.38M | 1.54M | 1.30M | 880.60K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 2.51M | 2.70M | 2.44M | 2.79M | 1.99M |
Operating Income | -2.51M | -2.70M | -2.42M | 13.21M | -1.99M |
Income Before Tax | -2.16M | -3.41M | -2.22M | 13.45M | -2.18M |
Income Tax Expenses | 2.07M | -- | -- | -- | 90.30K |
Earnings from Continuing Operations | -4.22M | -3.41M | -2.22M | 13.45M | -2.27M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -4.22M | -3.41M | -2.22M | 13.45M | -2.27M |
EBIT | -2.51M | -2.70M | -2.42M | 13.21M | -1.99M |
EBITDA | -2.50M | -2.70M | -2.42M | 13.21M | -1.98M |
EPS Basic | -1.00 | -0.81 | -0.53 | 4.67 | -2.71 |
Normalized Basic EPS | -0.30 | -0.37 | -0.31 | 2.92 | -1.51 |
EPS Diluted | -1.00 | -0.81 | -0.53 | 3.42 | -2.72 |
Normalized Diluted EPS | -0.30 | -0.37 | -0.31 | 2.16 | -1.51 |
Average Basic Shares Outstanding | 4.22M | 4.22M | 4.17M | 2.88M | 836.00K |
Average Diluted Shares Outstanding | 4.22M | 4.22M | 4.17M | 3.89M | 836.00K |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |